Ocrelizumab reduces thalamic volume loss in patients with RMS and PPMS.

Douglas Lorne ArnoldTill SprengerAmit Bar-OrJerry S Wolinsky Ludwig KapposShannon KolindUlrike BonatiStefano MagonJohan van BeekHarold KoendgenOscar BortolamiCorrado BernasconiLaura GaetanoAnthony Traboulsee

Published in: Multiple sclerosis (Houndmills, Basingstoke, England) (2022)

Ocrelizumab effectively reduced thalamic volume loss compared with IFNβ1a/placebo. Early treatment effects on thalamic tissue preservation persisted over time. Thalamic volume loss could be a potential sensitive marker of persisting tissue damage.

Keyphrases

deep brain stimulation
oxidative stress
immune response
dendritic cells
randomized controlled trial
clinical trial
study protocol
phase iii